Amit Kumar is a pharmacovigilance professional with over 6 years of experience. He currently works as an Assistant Manager at Tata Consultancy Services in Pune, India. Some of his key responsibilities include processing and quality reviewing ICSR, legal, and clinical trial cases. He also has experience writing PSUR/PADER/PBRER/DSUR reports. Previously he has worked at Cognizant Technology Solutions and Claris Lifesciences in pharmacovigilance roles. He holds an M.Pharm and B.Pharm from Birla Institute of Technology.
“Pharmaceutical Quality Matrices in determining overall state of Quality and ...Marcep Inc.
Introduction to Quality Matrices
•What is Quality metrics
Background&Glossary
•Modernization of Regulatory Oversight of Drug Quality and Promotion of Post-Approval Improvements
•Use of Quality Metrics by FDA for Risk-Based Inspection Scheduling and Prediction of Drug Shortages
Legal authority
•Records Associated with the Process Validation Lifecycle and PQS Assessment
•Authority to Inspect Records and Request in Advance of or In Lieu of an Inspection
The Use of Quality Metrics and Effect of Non-Reporting
•How FDA Intends to Use Quality Metrics
•Effect of Non-Reporting
Group Discussion:
Implementing Trending of Quality Indices in Your Organization
The importance of the right culture and people
• Role of leadership in trending of Quality Indices
• Developing anonline data base for Quality Indices
•Analysis, interpretation and reporting of Quality Indices
The Process Flow
• Establishing the ground rules, procedures, forms and mechanismfor data collection for Quality indices
• Determining responsibilities and roles for the implementation of trending of Quality Indices
Starting the Quality Indices Management Process
•Review of Quality Indices and Gap evaluation
•Preparation of Data bases for Data acquisition
•Collection data for completeness and Accuracy
•Processing and Reporting of Quality Metrics
Day Two
Reporting of Quality data and Calculation of Quality Metrics
• Who Reports and Who May Contribute to the Report
• Quality Metrics that FDA Intends to Calculate
• What Quality Data Would Be Reported
• How to Report Quality Data to FDA
Instructions for Quality Metric Data Submission
•Worksheet for Data Tables
•Product Specific Information
•Mandatory Data •ICH Q9
•Optional Metrics
Recognizing and Understanding the Trending of Quality Indices
Working Session, I:
•Participants will be divided into groups and given acase study and be asked to perform a trend analysis on a given data. Each group will present theresults of its analysis
Working Session II:
•Participants will be divided into groups and given acase study and be asked to perform a trend analysis and propose a Quality metric by using Risk Based approach for the specific set of data. The results of the analyses willbe shared in the class.
Complexities of Implementation Quality Metrics
•Overcoming the pitfalls
•Benefits and Risks
General Discussion and Questions
The 7 Deadly Sins of Quality Assurance and Quality Control - Pharma IQ eBookPharma IQ
The Seven Sins of QA and QC are those transgressions which are detrimental to quality and profitability. You will probably commit some of them every day. We asked the global pharmaceutical community what they thought were the biggest sins that people commit in quality assurance and quality control and the same ones kept coming up over and over again.
The 2012 Food and Drug Administration Safety and Innovation Act (FDASIA) includes a provision that allows sponsors to request that their drug be designated as a "Breakthrough Therapy". This designation is primarily based on the early clinical finding of substantial efficacy in s serious medical need indication. A Breakthrough Therapy Designation provides fast track program advantages alongside a frequent FDA guidance on an efficient drug development program. The FDA also makes an organizational commitment to involve experienced reviewers and senior management in such guidance. This presentation provides an overview of Breakthrough Therapy Designation and discusses why CMC aspects can lag-behind clinical development and how this may be addressed.
The time has come to seriously work on leveraging End-of-Phase II for setting regulatory specifications.
“Pharmaceutical Quality Matrices in determining overall state of Quality and ...Marcep Inc.
Introduction to Quality Matrices
•What is Quality metrics
Background&Glossary
•Modernization of Regulatory Oversight of Drug Quality and Promotion of Post-Approval Improvements
•Use of Quality Metrics by FDA for Risk-Based Inspection Scheduling and Prediction of Drug Shortages
Legal authority
•Records Associated with the Process Validation Lifecycle and PQS Assessment
•Authority to Inspect Records and Request in Advance of or In Lieu of an Inspection
The Use of Quality Metrics and Effect of Non-Reporting
•How FDA Intends to Use Quality Metrics
•Effect of Non-Reporting
Group Discussion:
Implementing Trending of Quality Indices in Your Organization
The importance of the right culture and people
• Role of leadership in trending of Quality Indices
• Developing anonline data base for Quality Indices
•Analysis, interpretation and reporting of Quality Indices
The Process Flow
• Establishing the ground rules, procedures, forms and mechanismfor data collection for Quality indices
• Determining responsibilities and roles for the implementation of trending of Quality Indices
Starting the Quality Indices Management Process
•Review of Quality Indices and Gap evaluation
•Preparation of Data bases for Data acquisition
•Collection data for completeness and Accuracy
•Processing and Reporting of Quality Metrics
Day Two
Reporting of Quality data and Calculation of Quality Metrics
• Who Reports and Who May Contribute to the Report
• Quality Metrics that FDA Intends to Calculate
• What Quality Data Would Be Reported
• How to Report Quality Data to FDA
Instructions for Quality Metric Data Submission
•Worksheet for Data Tables
•Product Specific Information
•Mandatory Data •ICH Q9
•Optional Metrics
Recognizing and Understanding the Trending of Quality Indices
Working Session, I:
•Participants will be divided into groups and given acase study and be asked to perform a trend analysis on a given data. Each group will present theresults of its analysis
Working Session II:
•Participants will be divided into groups and given acase study and be asked to perform a trend analysis and propose a Quality metric by using Risk Based approach for the specific set of data. The results of the analyses willbe shared in the class.
Complexities of Implementation Quality Metrics
•Overcoming the pitfalls
•Benefits and Risks
General Discussion and Questions
The 7 Deadly Sins of Quality Assurance and Quality Control - Pharma IQ eBookPharma IQ
The Seven Sins of QA and QC are those transgressions which are detrimental to quality and profitability. You will probably commit some of them every day. We asked the global pharmaceutical community what they thought were the biggest sins that people commit in quality assurance and quality control and the same ones kept coming up over and over again.
The 2012 Food and Drug Administration Safety and Innovation Act (FDASIA) includes a provision that allows sponsors to request that their drug be designated as a "Breakthrough Therapy". This designation is primarily based on the early clinical finding of substantial efficacy in s serious medical need indication. A Breakthrough Therapy Designation provides fast track program advantages alongside a frequent FDA guidance on an efficient drug development program. The FDA also makes an organizational commitment to involve experienced reviewers and senior management in such guidance. This presentation provides an overview of Breakthrough Therapy Designation and discusses why CMC aspects can lag-behind clinical development and how this may be addressed.
The time has come to seriously work on leveraging End-of-Phase II for setting regulatory specifications.
Process Analytical Technology, Quality by Design & PharmacogenomicsAjaz Hussain
Keynote address at the 2013 Scientific Conference of the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas (NAPPSA). The lecture attempts to 'connect the dots' between PAT and QbD to Pharmacogenomics in the context of the authors experience at the US FDA and in industry.
What is Medical Auditing? How it can be Performed?Jessica Parker
Medical auditing entails conducting internal or external reviews of coding accuracy, policies, and procedures to ensure you are running an efficient and hopefully liability-free operation. Quality health care is based on accurate and complete clinical documentation in the medical record. The best way to improve your clinical documentation and the livelihood of your health care organization is through medical record audits.
Alternative Approaches to FDA Approval for Drug and Device FirmsMichael Swit
Webinar sponsored by Compliance2Go focusing on different ways that drug and medical device firms can secure approval of products outside of traditional approaches. Presentation covers:
* accelerated approval
* fast track drugs
* priority review
* special 510(k)
* abbreviated 510(k)
Max Neeman International is India’s leading contract research organization providing full range of clinical development services to small, mid-size and global pharmaceutical, biotech and medical device companies.
Complying with Wearable Health Device RegulationTGA Australia
Complying with Wearable Health Device Regulation
• Which devices does the TGA regulate?
• How are devices approved?
• How does the TGA regulate devices once they are on the market?
Process Analytical Technology, Quality by Design & PharmacogenomicsAjaz Hussain
Keynote address at the 2013 Scientific Conference of the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas (NAPPSA). The lecture attempts to 'connect the dots' between PAT and QbD to Pharmacogenomics in the context of the authors experience at the US FDA and in industry.
What is Medical Auditing? How it can be Performed?Jessica Parker
Medical auditing entails conducting internal or external reviews of coding accuracy, policies, and procedures to ensure you are running an efficient and hopefully liability-free operation. Quality health care is based on accurate and complete clinical documentation in the medical record. The best way to improve your clinical documentation and the livelihood of your health care organization is through medical record audits.
Alternative Approaches to FDA Approval for Drug and Device FirmsMichael Swit
Webinar sponsored by Compliance2Go focusing on different ways that drug and medical device firms can secure approval of products outside of traditional approaches. Presentation covers:
* accelerated approval
* fast track drugs
* priority review
* special 510(k)
* abbreviated 510(k)
Max Neeman International is India’s leading contract research organization providing full range of clinical development services to small, mid-size and global pharmaceutical, biotech and medical device companies.
Complying with Wearable Health Device RegulationTGA Australia
Complying with Wearable Health Device Regulation
• Which devices does the TGA regulate?
• How are devices approved?
• How does the TGA regulate devices once they are on the market?
The aim of Safety reports is describe the safety during the lifecycle of the medicinal product. These reports are necessary during development as well as during the authorization process or renewal. In addition, several of these reports may be required by Health Authorities in case of safety concerns.
This presentation contains a full overview about periodic safety update reports and all the information related with it.
Advanced pg diploma in pharmacovigilance drug safety in oracle argus safety d...BioMed Informatics
BioMed Informatics Medwin Hospitals is a leading Clinical Research Organization offering full range of Pharmacovigilance, Clinical Research, Clinical Data Management, Oracle Clinical OC/RDC, Oracle Argus Safety, SAS Clinical, Regulatory Affairs&SAS CDISC SDTM, ADaM, TLF/TLGs trainings since the year of 2000that are helpful for Life Sciences/Pharmacy students to enter into IT Companies and Pharma, Biotech, CRO industries.
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...László Árvai
The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Bluefish Pharmaceuticals.
Pharmacovigilance Training in Oracle Argus Safety Database with ProjectBioMed Informatics
Pharmacovigilance Training in Oracle Argus Safety Database with Project
BioMed Informatics Medwin Hospitals
BioMed Informatics Medwin Hospitals is a leading Clinical Research Organization offering full range of Clinical Research, Clinical Data Management, Oracle Clinical OC/RDC, Pharmacovigilance, Oracle Argus Safety, SAS Clinical, IPR & Regulatory Affairs trainings since the year of 2000 that are helpful for Life Sciences/Pharmacy students to enter into IT Companies and Pharma, Biotech, CRO industries.
Oracle Argus Safety is an advanced and comprehensive adverse events (AE) management system that helps life sciences companies enable regulatory compliance, drive product stewardship, and integrate safety and risk management into one comprehensive platform. Argus Safety is industry-proven and accepted, having been used for more than a decade at leading Pharmaceutical, Biotech, CRO, and IT Companies. Trainees get hands on practical training experience to create career paths.
Mode of Training: Instructor Led Class room/Online Training
Online Training Features:
Web based classroom
One faculty/student
Placement support
Regular/Fast track/Weekend batches
Flexible timings
Training Mode: Skype/Teamviewer
Hands-On Training on the Database
Direct access to Oracle Argus Safety Database
Our candidates employed in Novartis, Quintiles, TCS, Parexel International (India) Pvt Ltd, MakroCare, Global Hospitals, Apollo Hospitals, NIMS, Glenmark Pharmaceuticals Ltd, Jubilant, Reliance Life Sciences, Shantha Biotechnics Ltd, Mahindra Satyam, SMO Clinical Research (I) Pvt Ltd, Pioneer Corporate Services Inc-USA, ICMR, AstraZeneca-UK, Texas Woman’s University-USA and many more…
Certification
Certificate will be provided for this course on successful completion of Assignments & Projects. Certificate would be awarded at the end of the program by BioMed Informatics Medwin Hospitals.
Interested candidates are kindly requested to fill the enquiry form in the website www.biomedlifesciences.com for further information.
Please note that we also provide separate hostel facility assistance for ladies as well as gents.
Contact:
G.V.L.P. Subba Rao
BioMed Informatics
Medwin Hospitals B Block First Floor,
Nampally, Hyderabad-500 001, India
Phone: 040 - 40209750
Website: www.biomedlifesciences.com
Performance Testing for Mobile Apps & Sites using Apache JMeterAlon Girmonsky
Mobile testing has many moving parts
- Different devices
- Different mobile networks
- Less tolerance for bad user experience
Therefore any platform that is being used for testing, must support all these by providing easy ways to record mobile scenarios and to be able to realistically emulate mobile traffic at scale.
On the occasion of Discussion Forum on ICH Q7 & ICH Q11 of more than 450 experienced practicing professionals gathering of pharmaceutical manufacturing industry scheduled at ICCBS, University of Karachi organized by CCK on 23 April 2017
A detail-oriented, sincere and hardworking individual with a Master of Science and Over Fourteen years of GLP/GMP work experience
Expert in Audit trails review in Empower, Lab solutions, Tiamo and other softwares.
Experience in theoretical and practical knowledge in calibration, preventive maintenance, troubleshooting and problem solving of critical equipment like HPLC, GC, Auto Titrator,DR and UV-Spectrophotometer etc.
A compliant CER should support strong clinical evidence that your device achieves its intended purpose without exposing users and patients to risk. The CER must be based on clinical data, which may include clinical data from existing literature, clinical experience, clinical trials, or any combination of the three.
You are required to prepare and submit a clinical evaluation report with your technical file as part of the CE Marking/conformity assessment process. However, approach the CER as a standalone document.
Do you know how many rewarding job opportunities exist in the Clinical resea...Access-Pharma Jobs
If you are a BSc/MSc/PhD or MD/PharmD in career change, you can see some of the available career opportunities in the Clinical research industry and how to get in this field in this presentation made on Jan 14, 2017 at the Pharmacolloque 2017:
https://cra-school.com/news/
Ian brings 16 years of experience in the Biotech/Pharmaceutical Industry in Quality Assurance and Quality Control. He has extensive knowledge of all of the applicable regulatory requirements.
My last projects as an independent contractor were with SHIRE, LONZA and NOVARTIS. I conducted Product Investigations from Inoculations of Media to Manufacturing projects which included from line clearance issues to inclusions of foreign material. Also, Inspection of all product packaging to determine a non-negative product impact.
It's an assignment on selected topics on Pharmaceuticals. Which are
1. Quality Management system in Pharmaceutical Industry
2. Quality Assurance and Quality Control in Pharmaceutical Industry
3. Difference between Quality Assurance and Quality Control
4. Briefly describe Pharmacopoeia, Drug Formulary, Drug compendia,
Pharmaceutical codex
5. Short notes on British Pharmacopoeia, US Pharmacopoeia,
European Pharmacopoeia, Japanese Pharmacopoeia, British
Pharmaceutical Codex
6. What is monograph in Pharmacopoeia? What does it contain?
Max Neeman International is India’s leading contract research organization providing full range of clinical development services to small, mid-size and global pharmaceutical, biotech and medical device companies. The portfolio of the services include comprehensive Phase II-III clinical trials, regulatory submissions, phase IV post approval programs & commercialization services.
1. Amit Kumar
Contact: +91-9561076789, +91-8793114988
E-Mail: amit2713@gmail.com
Aspiring to scale heights in drug safety reporting as per Regulatory expectations with a Pharmaceutical
organisation of high repute.
Professional Abridgement
∞ A dynamic individual with more than 6 years of experience.
∞ Working in Tata Consultancy Services, Pune, India as an Asst. Manager in Pharmacovigilance Division.
∞ Experience in processing and quality reviewing of ICSR, Legal, and Clinical trial cases.
∞ Experience in PSUR/PADER/PBRER/DSUR writing.
∞ Exceptionally organised with a track record that demonstrates creativity and initiatives to achieve set goals.
∞ Skilfully handled and co-ordinated different bioanalytical, clinical research and drug safety projects.
∞ Experience in setting up of a Pharmacovigilance System for EU and US market.
∞ Monitored Clinical Trials as a sponsor in various CROs. Conducted audit for Clinical trial studies as a sponsor in
CROs.
∞ Initiated Post-marketing surveillance studies.
∞ A proactive learner with a flair for adopting emerging trends & addressing industry requirements to achieve
organisational objectives & profitability norms.
∞ Holds exceptional team spirit thereby helping in easy achievement of organisational & personal goals.
∞ An effective communicator with excellent relationship building & interpersonal skills.
Academe
M.Pharm (Pharmaceutics)
Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India in 2008. Obtained 74.5% marks.
B.Pharm.
Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India in 2006. Obtained 74.0% marks.
Senior Secondary (Science)
C.B.S.E. Board, India in 2000. Obtained 61.4% marks.
Secondary
C.B.S.E. Board, India in 1998. Obtained 69% marks.
Work Experience
TATA CONSULTANCY SERVICES, PUNE, INDIA: 05th
Jul 2012 to till date
• 05th
Jul 2012 to 31st
Mar 2013 as Process Executive (Pharmacovigilance)
• 01st
Apr 2013 to 31st
Mar 2015 date as Business Process Lead (Pharmacovigilance)
• 01st
Apr 2015 to till date as Assistant Manager (Pharmacovigilance) [Mail confirmation received; letter
awaited]
• Perform safety periodic writing including assessment, analysis, and Quality control of all reports
[PBRER/PSUR/DSUR/QR/QSUR/SPR SA].
• Schedule and conduct Kick-off meeting for preparation of report.
• To contribute towards a team in Drug Safety offering Pharmacovigilance services to Clients delivering a
1 of 5
2. high quality data in stipulated timelines
• Provide technical expertise to Pharmacovigilance/Drug Safety team
• Address Performance Improvement Plans
• Manage and coordinate across Pharmacovigilance/Drug Safety sub-processes (Client specific)
• Ensure compliance to SOPs
• Perform tasks/activities as communicated by the Project Manager.
• Archiving of all safety related documents in EPIC.
• Assist in developing and implementing new techniques in Pharmacovigilance/Drug Safety activities
• Develops strategies in co-ordination with other Team leads and Project Managers so as to meet quality
requirements efficiently and meet timelines set by the client.
- Provide training in:
The operational techniques and activities undertaken within the Pharmacovigilance/Drug
Safety Unit Amgen Pharmacovigilance/Drug Safety SOPs and other standards
Undertake training related to a project to Pharmacovigilance/Drug Safety team
members.
• Escalation of identified unresolved issues to Project manager on time
• Ensure that projects are completed as per agreed timelines.
• Interactions and telecons - Coordinate and communicate effectively with primary contacts at Client
teams to ensure satisfactory progress of project work and timely resolution of issues
• Monitor and track SLAs /Metrics on a project basis.
• Act as a gatekeeper for the changes requested to product, service or process (client specific)
• Solid experience and understanding of USFDA regulations, EU regulations, ICH guidelines, GCP
principles, clinical drug development process, organizational, strategic, communication and inter-
personnel skills
Project Involvement:
1. ICSR Case Processing
Reporting to: Assistant Manager
2. Clinical Trial Case Processing
Reporting to: Assistant Manager
3. Pharmacovigilance Standards (Aggregate Report Writing)
Reporting to: Project Manager
- Additional responsibilities (since 14th
Jul 2014): Working as a Subject Matter Expert (Pharmacovigilance).
Tools using at TCS:
1. Argus ver. 7.0
2. EDC Rave
3. MedDRA ver. 17.1
4. EPIC
Notice Period: 3 months
COGNIZANT TECHNOLOGY SOLUTIONS, MUMBAI, INDIA: 03rd
Jan 2011 to 08th
Jun 2012 as Jr. Data Analyst
Job Role: Safety Processing Expert / PSUR writer
• Receive information on adverse events, perform initial checks, search database to prevent duplicate entries,
create case file and initialize received drug safety reports in the DS&E tracking tool and/or safety database
(Argus).
• Ensure scientific rigor through accurate, complete and consistent data entry of adverse event reports from
source documents including petitions with emphasis on timeliness and quality.
• Evaluate and finish processing of expeditable & non-expeditable AE reports, including review for
completeness and accuracy.
• Use medical dictionaries and business guidances to code medical history, drugs and adverse event terms.
Prepare narratives summarizing the essential details of the case.
• Identify clinically relevant information missing from case report and facilitate its collection (in consultation
2 of 5
3. with medical staff as required) by preparing follow-up request as needed.
• Alert manager to potential safety signals based on incoming case reports.
• Work with Client’s country safety departments along with US legal processing department, Clinical Safety
Scientists and pharmacovigilance leaders to ensure that reports are accurately collected, evaluated and
databased.
• Assist Cognizant Team manager with related administrative and procedural activities as required or
requested.
• Assists in the training of other Safety Processing Experts as necessary and provide mentorship to new
joinees.
• Writing of quality PSUR within specified timelines as per the Client’s SOPs and and current
Pharmacovigilance regulations and guideline,
• Peer review/QC of PSURs prepared by fellow PSUR writers.
Projects:
1. ICSR Case Processing
a. Reporting to: Team Leader
b. Database: ARGUS ver. 4.2
c. Medical Coding: MedDRA Ver. 13.1
2. Legal Case Processing
a. Reporting to : Service Delivery Manager
b. Database: ARGUS ver. 4.2
c. Medical Coding: MedDRA Ver. 14.1
3. PSUR writing
a. Reporting to: Service Delivery Manager
CLARIS LIFESCIENCES LIMITED, AHEMDABAD, INDIA- as Jr Executive in the Pharmacovigilance division of
I.R.A. deptt: 01st
Jun 2010 to 29 Nov 2010
Job Responsibilities
• Responsible for Pharmacovigilance activity in US market as a team lead at Claris Head Quarter.
• Allocation of daily pharmacovigilance activities and ensure its completion within specified time as per the
current SOPs and regulations.
• Preparation & Review SOPs for Pharmacovigilance.
• Receive ADRs from partners / QPPV / Medical agencies.
• Receive line listing from QPPV and maintain record.
• Designing the protocol, records, procedure for pharmacovigilance for USA in compliance to various
regulatory guidelines.
• Communicate and provide required information to QPPV.
• Processing and reviewing Medwatch 3500A form against the source document.
• Preparation of cover letters for reports submitting to regulatory authorities.
• Preparation of Periodic reports (PSUR/AR/PADER).
• Prepare responses for regulatory queries related to Safety of the products.
• Communicate and establish safety agreement with Partners (US / Canada).
• Collection of safety information from research articles, review papers throughout search engine, journals
and books and inform to relevant department.
• Elaborate understanding and application of MHRA, US FDA and ICH guidelines.
• Assist in initiating Post marketing surveillance study for the company’s products.
• Preparation and maintenance of tracking sheets and reconciliation report.
• Conducting in-house periodic audit for Pharmacovigilance system with respect to expectations described
under US FDA and MHRA guidelines and Good Pharmacovigilance Practices.
• Designing of clinical trial includes reviewing, protocol, case record form and all related
3 of 5
4. work in compliance to GCP guidelines.
• Monitoring of Clinical trials and BE studies at the Service provider’s site. Periodic visit to the site and
maintaining rapport between Company, Investigators, and Volunteers.
• Conduct in-process and documentation audit at CROs as a sponsor of the study.
RANBAXY LABORATORIES LIMITED, as Research Associate – Clinical Pharmacology and
Pharmacokinetics: 30 Sep 2008 to 20 May 2010
• Development and maintaining GLP compliance in Bio-analytical laboratory and conduct all experiments in
conformance to SOPs and current regulations to produce quality data.
• Coordinate effective planning, set-up, management and closeout of clinical trials in order to meet the applicable
GCP/GLP standards.
• Ensure effective technology transfer during the analytical and bioanalytical methods between the R&D and allied
company (Terapia Ranbaxy) or CROs.
• Support the senior management with the organizational activities of clinical trial management.
• Prepare and review of technical documents, including response to QA audits, Method Validation reports, study
forms (Raw Data Sheets) for error free Bio-analytical methods.
• Develop and Validate cost effective, reproducible and rugged bioanalytical method for the determination of
analyte(s) in biological matrix for the bioequivalence studies and write method SOP for the same.
• Process and analyze biological samples using LCMS/MS system.
• Online documentation of each and every activity as per the current SOPs, GLP and regulatory guidelines.
• Databasing each result in Nugenesis Database.
• Coordinating different bioanalytical assigned projects and maintaining the timelines for each activity viz. method
development, validation and analysis.
Certifications and Awards
Recipient of BPS-Performance Linked Reward on 23 Jan 2014 from Tata Consultancy Services for
outstanding contribution in the Organization.
Recipient of BPS-Performance Linked Reward on 03 Sep 2014 from Tata Consultancy Services for
outstanding contribution in the Organization.
Received Process Excelentia Award for Quarter-2 2011 from Cognizant for quality performance in ‘Novartis
Legal Case Processing’.
Received Opel Award 2011 from Cognizant for outstanding performance, productivity and dedicated service.
Qualified GATE 2006 with 95.4 percentile.
Workshop/Seminars attended
1. Title : Monolithic Columns- Applications (2009)
Organised by: Merck Ltd
Venue : New Delhi.
2. Title : The SME (Subject Matter Expert) Career Path Program (14th – 16th Jul 2014)
Organized by: Tata Consultancy Services
Venue: Mumbai
• Attended 56th Indian Pharmaceutical Congress (2004), Kolkata, India.
Academic Projects Handled
M. Pharm.
4 of 5
5. Project Title: Effect of Diluents on solid- state Stability and Thermal Behaviour of Ibuprofen
B. Pharm.
Project Title: Application of the Concept of Osmotic Pressure in the Development of Osmotic Pump
Unique Drug Delivery Device.
Computer Proficiency
MS Tools: MS Word, MS Excel, MS Powerpoint
Data Analysing Programs: Analyst software (Version 1.4.0 and 1.4.1), TA 60,
Graph Pad Instat, Graph Pad Prism
Operating Systems: Windows XP/Vista/ Windows 7
Database: ARGUS 5.1, Nugenesis, EDC Rave
Medical coding tools: MedDRA, WHO Drug Dictionary, ICD-9
Personal Dossier
Date of Birth: 27th
January, 1983
Address for communication: S/O Sri Ganesh Saw, Quarter Number: 3-112, Sector: 2A, Bokaro Steel City- 827001
(Jharkhand) India
Permanent Address: At- Telmunga, Post- Kasmar, Distt. Bokaro PIN- 829115 (Jharkhand), India
I hereby declare that the particulars mentioned above are correct to the best of my knowledge and belief.
Date: 08 May 2015
Place: Pune, India Amit Kumar
5 of 5
6. Project Title: Effect of Diluents on solid- state Stability and Thermal Behaviour of Ibuprofen
B. Pharm.
Project Title: Application of the Concept of Osmotic Pressure in the Development of Osmotic Pump
Unique Drug Delivery Device.
Computer Proficiency
MS Tools: MS Word, MS Excel, MS Powerpoint
Data Analysing Programs: Analyst software (Version 1.4.0 and 1.4.1), TA 60,
Graph Pad Instat, Graph Pad Prism
Operating Systems: Windows XP/Vista/ Windows 7
Database: ARGUS 5.1, Nugenesis, EDC Rave
Medical coding tools: MedDRA, WHO Drug Dictionary, ICD-9
Personal Dossier
Date of Birth: 27th
January, 1983
Address for communication: S/O Sri Ganesh Saw, Quarter Number: 3-112, Sector: 2A, Bokaro Steel City- 827001
(Jharkhand) India
Permanent Address: At- Telmunga, Post- Kasmar, Distt. Bokaro PIN- 829115 (Jharkhand), India
I hereby declare that the particulars mentioned above are correct to the best of my knowledge and belief.
Date: 08 May 2015
Place: Pune, India Amit Kumar
5 of 5